Anti-Growth, Anti-Angiogenic, and Pro-Apoptotic Effects by CX-4945, an Inhibitor of Casein Kinase 2, on HuCCT-1 Human Cholangiocarcinoma Cells via Control of Caspase-9/3, DR-4, STAT-3/STAT-5, Mcl-1, eIF-2α, and HIF-1α

• Published in: International journal of molecular sciences 2022-06, Vol.23 (11), p.6353
• Main Authors: Wang, Saini, Yadav, Anil Kumar, Han, Jin-Yi, Ahn, Keun Soo, Jang, Byeong-Churl
• Format: Article
• Language: English
• Subjects: Angiogenesis; Antiangiogenics; Apoptosis; Bile Duct Neoplasms - drug therapy; Bile Ducts, Intrahepatic; Cancer therapies; Casein; Casein kinase II; Casein Kinase II - genetics; Caspase 9; Cell Line, Tumor; Cholangiocarcinoma; Cholangiocarcinoma - drug therapy; CK2; CX-4945; DNA fragmentation; Enzyme inhibitors; Eukaryotic Initiation Factor-2; Experiments; HIF-1α; HuCCT-1; Humans; Hypoxia-inducible factor 1a; Kinases; Mcl-1; Mcl-1 protein; Medical prognosis; Naphthyridines; Phenazines; Phosphorylation; Poly(ADP-ribose) polymerase; Protein expression; Proteins; STAT-3; Stat3 protein; Stat5 protein; Substrate inhibition; Survival
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23116353

Overexpression of casein kinase 2 (CK2) has an oncogenic and pro-survival role in many cancers. CX-4945 (Silmitasertib) is a CK2 inhibitor with anti-cancerous and anti-angiogenic effects. Up to date, the anti-cancer effect and mechanism of CX-4945 on human cholangiocarcinoma (CCA) remain unclear. This study investigated whether CX-4945 inhibits growth and induces apoptosis of HuCCT-1 cells, a human CCA cell line. Of note, treatment with CX-4945 at 20 μM markedly reduced survival and induced apoptosis of HuCCT-1 cells, as evidenced by nuclear DNA fragmentation, PARP cleavage, activation of caspase-9/3, and up-regulation of DR-4. Although CX-4945 did not affect the phosphorylation and expression of CK2, it vastly inhibited the phosphorylation of CK2 substrates, supporting the drug's efficacy in inhibiting CK2 and its downstream pathway. Importantly, knockdown of CK2 that partially suppressed the phosphorylation of CK2 substrates resulted in a significant reduction of HuCCT-1 cell survival. In addition, CX-4945 reduced the phosphorylation and expression of STAT-3 and STAT-5 in HuCCT-1 cells, and pharmacological inhibition or respective knockdown of these proteins resulted in significant growth suppression of HuCCT-1 cells. CX-4945 also had abilities to decrease Mcl-1 expression while increasing eIF-2α phosphorylation in HuCCT-1 cells. Furthermore, there was a time-differential negative regulation of HIF-1α expression by CX-4945 in HuCCT-1 cells, and knockdown of HIF-1α caused a significant reduction of the cell survival. In summary, these results demonstrated that CX-4945 has anti-growth, anti-angiogenic, and pro-apoptotic effects on HuCCT-1 cells, which are mediated through control of CK2, caspase-9/3, DR-4, STAT-3/5, Mcl-1, eIF-2α, and HIF-1α.